Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The rise of antibiotic resistance in many pathogens has been driven by the spread of a small number of strains, suggesting that some bacteria may be genetically pre-disposed to evolving resistance. Researchers at Oxford University have tested this hypothesis by quantifying differences in evolvability between pathogen strains and by searching for ‘potentiator’ genes that accelerate the evolution of resistance. Their results are published today in Nature Communications.

Bacterial colonies growing on agar plates © Andrei Papkou

Scientists from the Department of Zoology, Oxford University, show that a single gene that codes for an efflux pump predisposes some strains of pathogenic S.aureus to evolve high levels of ciprofloxacin resistance. Bacterial efflux pumps actively pump out chemicals from bacterial cells – sort of like a bacterial bucket brigade – and this an important way that bacteria cope with exposure to a range of toxic chemicals, including antibiotics.

Their experiments involved a common human pathogen, Staphylococcus aureus, that is an important source of antibiotic resistant infections in health care settings (ie MRSA). They used a broad-spectrum antibiotic called ciprofloxacin that was developed in the 1980s, and initially heralded as a solution to MRSA infections.

The full article is available on the University of Oxford website

Similar stories

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.